Summit Therapeutics (SMMT) Surges 80% on Sarepta (SRPT) Deal

October 4, 2016 8:56 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Summit Therapeutics (NASDAQ: SMMT) is trading up 80% in pre-open trade after the company entered an exclusive license and collaboration agreement granting Sarepta (NASDAQ: SRPT) rights in Europe, as well as in Turkey and the Commonwealth of Independent States (‘the licensed territory’), to Summit’s utrophin modulator pipeline, including its lead clinical candidate, ezutromid, for the treatment of Duchenne muscular dystrophy.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Momentum Movers, Trader Talk

Related Entities

Pre Market Movers

Add Your Comment